Therapies for hematologic malignancies
The invention provides methods that relate to a novel therapeutic strategy for the treatment of hematological malignancies and inflammatory diseases. In particular, the method comprises administration of a compound of formula A, wherein R is H, halo, or C1-C6 alkyl; R′ is C1-C6 alkyl; or a pharmaceutically acceptable salt thereof; and optionally a pharmaceutically acceptable excipient.
1. A method for treating a hematological malignancy in a subject in need thereof, comprising administering a compound of formula I″
or a pharmaceutically acceptable salt thereof, and bortezomib.
2. The method according to claim 1 , wherein said hematological malignancy is leukemia or lymphoma.
3. The method according to claim 1 , wherein said hematological malignancy is selected from the group consisting of mantle cell lymphoma (MCL), multiple myeloma (MM), chronic lymphocytic leukemia (CLL), non-Hodgkin's lymphoma (NHL), acute lymphocytic leukemia (ALL), acute myeloid leukemia (AML), small lymphocytic lymphoma (SLL), follicular lymphoma, Waldenstrom's macroglobulinemia (WM), and B-cell lymphoma and diffuse large B-cell lymphoma (DLBCL).
4. The method according to claim 1 , wherein the subject is refractory to chemotherapy treatment or is in relapse after treatment with chemotherapy.
5. The method according to claim 1 , further comprising administering at least one additional therapeutic agent.
6. The method according to claim 1 , comprising administering to said subject a pharmaceutical composition comprising the compound of formula I″ or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable excipient.
7. The method according to claim 1 , wherein said subject has at least one enlarged lymph node.
8. The method according to claim 4 , wherein said subject is refractory to at least two standard or experimental chemotherapy treatments.
9. The method according to claim 1 , wherein said compound of formula I″ or a pharmaceutically acceptable salt thereof is administered at a dose of 50-350 mg BID.
10. The method according to claim 9 , wherein said compound of formula I″ or a pharmaceutically acceptable salt thereof is administered at a dose of 150 mg BID.